Some patients using Eliquis, a new generation anticoagulant introduced in 2013, have reported uncontrollable bleeding as a serious side effect and charge the drug makers — Pfizer and Bristol Myers Squibb — with failing to warn consumers about this potentially deadly side effect.
When it was introduced, Eliquis was marketed as a safer, more convenient blood-thinning drug than warfarin. It is often prescribed to patients who have recently undergone replacement knee or hip surgery, where blood clot formation is likely.
Like other blood thinners, Eliquis works by inhibiting the clotting process and improving circulation. Unfortunately, the drug’s effects halt the body’s ability to heal from any internal bleeding event, which can be life threatening to patients.
While warfarin does have a bleeding antidote, Eliquis and other drugs in its class — Xarelto and Pradaxa — have not had a widely available reversal agent to halt uncontrollable bleeds. Some of the injuries caused by complications from taking Eliquis have included:
- Brain bleeds
- Brain hemorrhage
- Gastrointestinal bleeding
- Kidney bleeding
- Blood in the eyes
Patients who have suffered adverse bleeding events due to Eliquis have filed product liability claims, alleging that the drug’s manufacturers did not specifically warn against uncontrollable bleeding side effects for patients on Eliquis and marketing the drug as a safer alternative. Internal bleeding symptoms can include:
- Blood in the urine
- Coughing up blood
- Bloody stools
- Nose bleeds
- Vomiting up blood
- Joint Pain
If you have taken Eliquis or any other blood thinner and experienced uncontrollable bleeding, you should speak with an experienced personal injury attorney to determine if you have a claim.
Roberts & Roberts focuses on helping people who have been injured in accidents or have been the victim of faulty medical products like Eliquis. Please call 800-248-6000 or contact us for a free consultation with our experienced personal injury legal team for the compassionate representation you deserve.